LeMaitre Vascular (LMAT): Reevaluating Valuation Following Recent Decline in Share Price
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 30 2025
0mins
Source: Yahoo Finance
LeMaitre Vascular's Stock Performance: The company's shares are currently trading at $82.95, significantly below previous highs, with a year-to-date return of -9.31% and a 1-year total shareholder return of -21.75%, although long-term holders have seen substantial gains over 3 and 5 years.
Valuation Insights: Analysts peg LeMaitre Vascular's fair value at $104.78, indicating it is undervalued compared to its current price, but the company's high price-to-earnings ratio of 35.3 suggests potential risks if growth expectations are not met.
Growth Drivers: The company is experiencing robust growth in international markets, particularly through new product launches and regulatory approvals, which are expected to create significant new revenue streams.
Risks and Considerations: Emerging risks, such as challenges in maintaining pricing power and execution in new markets, could undermine the optimistic outlook, prompting investors to carefully evaluate the sustainability of the company's growth narrative.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LMAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LMAT
Wall Street analysts forecast LMAT stock price to rise
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 97.750
Low
93.00
Averages
105.20
High
120.00
Current: 97.750
Low
93.00
Averages
105.20
High
120.00
About LMAT
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. It develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which are used in open vascular surgery and dialysis access. It offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold globally in the United States, Europe, Canada and Asia Pacific.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LeMaitre Stock Performance Analysis and Outlook
- Market Performance: LeMaitre's stock has risen 15.5% over the past six months to $101.53 per share, outperforming the S&P 500's 11.3% gain, indicating some market appeal, yet analysts remain cautious about its future performance.
- Revenue Scale Limitations: With $256.3 million in revenue over the past 12 months, LeMaitre, as a small company, faces challenges in establishing trust in a heavily regulated industry, which limits its market potential and competitiveness.
- Valuation Analysis: Currently trading at a forward P/E of 32.9x, while the market holds an optimistic view of LeMaitre's future, analysts believe the stock has priced in too much good news, making it potentially less attractive as an investment.
- Alternative Investment Recommendations: Analysts suggest investors consider other stocks with greater growth potential, such as Nvidia and Tecnoglass, which have shown strong revenue growth in recent years, indicating a more favorable investment outlook.
See More
LeMaitre Vascular to Participate in Investor Conferences
- Investor Conference Schedule: LeMaitre Vascular will participate in the Jefferies Global Healthcare Conference on June 3, 2026, in New York City, engaging in a fireside chat at 10:30 AM EDT to showcase its expertise in treating peripheral vascular disease.
- Key Presentation Dates: The company will also present at the Goldman Sachs Annual Global Healthcare Conference on June 10, 2026, in Miami Beach at 9:20 AM EDT, further enhancing its visibility among investors.
- Market Demand Context: Peripheral vascular disease affects over 200 million people globally, and LeMaitre Vascular focuses on developing and manufacturing disposable and implantable vascular devices to meet the needs of vascular surgeons, highlighting its significant role in the medical device market.
- Company Positioning: By participating in these conferences, LeMaitre Vascular not only showcases its products and services but also strengthens its relationships with investors, driving future business growth and market expansion.
See More
LeMaitre Vascular Reports Strong Q1 2026 Earnings Growth and Strategic Outlook
- Significant Sales Growth: LeMaitre Vascular achieved an 11% sales increase in Q1 2026, with a gross margin of 72.7% and a 42% rise in EPS, indicating strong market performance and enhanced profitability.
- Outstanding Artegraft Performance: Artegraft has become the company's largest product, with worldwide sales growing 36% and international sales reaching $2.1 million, while 2026 sales are projected to hit $10 million, reflecting robust demand in international markets.
- Improved Profitability: Q1 operating income rose 41% year-over-year to $17.8 million, with an operating margin increasing from 21% in 2025 to 27%, demonstrating significant progress in cost control and efficiency improvements.
- Optimistic Future Outlook: The company affirmed its full-year revenue guidance of $280 million, expecting 12% organic growth, while raising EPS expectations to $3, showcasing management's confidence in future performance.
See More
LeMaitre Vascular Earnings Preview
- Revenue Beat: LeMaitre Vascular reported $64.45 million in revenue last quarter, a 15.7% year-over-year increase that not only surpassed analyst expectations but also provided strong support for next quarter's EPS guidance, indicating robust growth in the medical device sector.
- Optimistic Market Expectations: This quarter, the market anticipates an 11.4% year-over-year revenue growth for LeMaitre, aligning with the 12% increase recorded in the same quarter last year, reflecting analysts' optimistic outlook despite the company's history of missing Wall Street revenue estimates.
- Peer Performance Insights: In the healthcare equipment and supplies sector, Intuitive Surgical and Baxter reported revenue growth of 23% and 2.9%, respectively, exceeding analyst expectations, which may positively influence LeMaitre's performance by reflecting overall industry trends.
- Stable Stock Price: While the healthcare equipment sector saw an average stock price increase of 6% over the past month, LeMaitre's stock price remained unchanged at $108.97, with an average analyst price target of $111.22, indicating cautious optimism regarding its future growth potential.
See More
LeMaitre Vascular to Present at Needham Healthcare Conference
- Conference Presentation: LeMaitre Vascular will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2025, at 2:15 PM EDT, showcasing its latest advancements in treating peripheral vascular disease.
- Company Overview: LeMaitre Vascular focuses on providing devices, implants, and services for peripheral vascular disease, a condition affecting over 200 million people globally, highlighting its market potential and social responsibility.
- Product Development: The company develops, manufactures, and markets disposable and implantable vascular devices to meet the needs of its core customers, vascular surgeons, thereby driving business growth and increasing market share.
- Information Access: Additional information can be found on the company’s website www.lemaitre.com, demonstrating its commitment to transparency and effective communication with customers.
See More
LeMaitre Vascular Executive Sells Shares Amid Strong Growth
- Transaction Overview: On March 11, 2026, Trent G Kamke, Senior Vice President of Operations at LeMaitre Vascular, exercised and sold 2,625 shares of common stock for approximately $285,000, at a weighted average price of $108.50 per share, reflecting the company's strong stock performance.
- Ownership Change: This transaction reduced Kamke's direct holdings to 6,677 shares, representing 28.22% of his previous stake, indicating a significant shift in his equity position that could influence future decision-making and incentive structures.
- Financial Performance Highlights: LeMaitre reported a 16% year-over-year sales increase to $64.5 million in Q4 2025, with earnings rising 39% to $0.68 per share, supporting a 25% dividend increase, showcasing the company's robust growth potential in the medical device sector.
- Future Outlook: The company expects a 12% sales growth and a 22% increase in adjusted earnings for 2026, indicating LeMaitre Vascular's competitive strength and ongoing profitability, although analysts remain cautious about its future performance.
See More
LeMaitre Stock Performance Analysis and Outlook
- Market Performance: LeMaitre's stock has risen 15.5% over the past six months to $101.53 per share, outperforming the S&P 500's 11.3% gain, indicating some market appeal, yet analysts remain cautious about its future performance.
- Revenue Scale Limitations: With $256.3 million in revenue over the past 12 months, LeMaitre, as a small company, faces challenges in establishing trust in a heavily regulated industry, which limits its market potential and competitiveness.
- Valuation Analysis: Currently trading at a forward P/E of 32.9x, while the market holds an optimistic view of LeMaitre's future, analysts believe the stock has priced in too much good news, making it potentially less attractive as an investment.
- Alternative Investment Recommendations: Analysts suggest investors consider other stocks with greater growth potential, such as Nvidia and Tecnoglass, which have shown strong revenue growth in recent years, indicating a more favorable investment outlook.
See More
LeMaitre Vascular to Participate in Investor Conferences
- Investor Conference Schedule: LeMaitre Vascular will participate in the Jefferies Global Healthcare Conference on June 3, 2026, in New York City, engaging in a fireside chat at 10:30 AM EDT to showcase its expertise in treating peripheral vascular disease.
- Key Presentation Dates: The company will also present at the Goldman Sachs Annual Global Healthcare Conference on June 10, 2026, in Miami Beach at 9:20 AM EDT, further enhancing its visibility among investors.
- Market Demand Context: Peripheral vascular disease affects over 200 million people globally, and LeMaitre Vascular focuses on developing and manufacturing disposable and implantable vascular devices to meet the needs of vascular surgeons, highlighting its significant role in the medical device market.
- Company Positioning: By participating in these conferences, LeMaitre Vascular not only showcases its products and services but also strengthens its relationships with investors, driving future business growth and market expansion.
See More
LeMaitre Vascular Reports Strong Q1 2026 Earnings Growth and Strategic Outlook
- Significant Sales Growth: LeMaitre Vascular achieved an 11% sales increase in Q1 2026, with a gross margin of 72.7% and a 42% rise in EPS, indicating strong market performance and enhanced profitability.
- Outstanding Artegraft Performance: Artegraft has become the company's largest product, with worldwide sales growing 36% and international sales reaching $2.1 million, while 2026 sales are projected to hit $10 million, reflecting robust demand in international markets.
- Improved Profitability: Q1 operating income rose 41% year-over-year to $17.8 million, with an operating margin increasing from 21% in 2025 to 27%, demonstrating significant progress in cost control and efficiency improvements.
- Optimistic Future Outlook: The company affirmed its full-year revenue guidance of $280 million, expecting 12% organic growth, while raising EPS expectations to $3, showcasing management's confidence in future performance.
See More
LeMaitre Vascular Earnings Preview
- Revenue Beat: LeMaitre Vascular reported $64.45 million in revenue last quarter, a 15.7% year-over-year increase that not only surpassed analyst expectations but also provided strong support for next quarter's EPS guidance, indicating robust growth in the medical device sector.
- Optimistic Market Expectations: This quarter, the market anticipates an 11.4% year-over-year revenue growth for LeMaitre, aligning with the 12% increase recorded in the same quarter last year, reflecting analysts' optimistic outlook despite the company's history of missing Wall Street revenue estimates.
- Peer Performance Insights: In the healthcare equipment and supplies sector, Intuitive Surgical and Baxter reported revenue growth of 23% and 2.9%, respectively, exceeding analyst expectations, which may positively influence LeMaitre's performance by reflecting overall industry trends.
- Stable Stock Price: While the healthcare equipment sector saw an average stock price increase of 6% over the past month, LeMaitre's stock price remained unchanged at $108.97, with an average analyst price target of $111.22, indicating cautious optimism regarding its future growth potential.
See More
LeMaitre Vascular to Present at Needham Healthcare Conference
- Conference Presentation: LeMaitre Vascular will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2025, at 2:15 PM EDT, showcasing its latest advancements in treating peripheral vascular disease.
- Company Overview: LeMaitre Vascular focuses on providing devices, implants, and services for peripheral vascular disease, a condition affecting over 200 million people globally, highlighting its market potential and social responsibility.
- Product Development: The company develops, manufactures, and markets disposable and implantable vascular devices to meet the needs of its core customers, vascular surgeons, thereby driving business growth and increasing market share.
- Information Access: Additional information can be found on the company’s website www.lemaitre.com, demonstrating its commitment to transparency and effective communication with customers.
See More
LeMaitre Vascular Executive Sells Shares Amid Strong Growth
- Transaction Overview: On March 11, 2026, Trent G Kamke, Senior Vice President of Operations at LeMaitre Vascular, exercised and sold 2,625 shares of common stock for approximately $285,000, at a weighted average price of $108.50 per share, reflecting the company's strong stock performance.
- Ownership Change: This transaction reduced Kamke's direct holdings to 6,677 shares, representing 28.22% of his previous stake, indicating a significant shift in his equity position that could influence future decision-making and incentive structures.
- Financial Performance Highlights: LeMaitre reported a 16% year-over-year sales increase to $64.5 million in Q4 2025, with earnings rising 39% to $0.68 per share, supporting a 25% dividend increase, showcasing the company's robust growth potential in the medical device sector.
- Future Outlook: The company expects a 12% sales growth and a 22% increase in adjusted earnings for 2026, indicating LeMaitre Vascular's competitive strength and ongoing profitability, although analysts remain cautious about its future performance.
See More
